Notice of Proposed Sale · 144
Revolution Medicines, Inc.
RVMDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Revolution Medicines, Inc.
- Issuer CIK
- 0001628171
- SEC file number
- 001-39219
- Phone
- 6504816801
- Person for whose account securities are to be sold
- STEPHEN KELSEY
- Relationships to issuer
- Officer
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 92,531 | 18,816,178.85 | 214,336,418 | 09/11/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/11/2026 | Exercise of Stock Options | Issuer | 92,531 | N | 09/11/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| STEPHEN KELSEY | Common | 06/16/2026 | 4,175 | 651,797.66 |
Seller — prior-sale row 1, entry 1
- Name
- STEPHEN KELSEY
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 09/11/2026
- Signed
- /s/ Stephen Kelsey
- Plan adoption dates
- 06/12/2026
Company context
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by BAKER BROS. ADVISORS LP regarding Revolution Medicines, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Revolution Medicines, Inc.Nov 16, 2026
- 4 filingNov 13, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Revolution Medicines, Inc.Nov 5, 2026
- 10-Q filingNov 4, 2026